Genetic Characteristics and Clinical Outcomes of T-Cell Acute Lymphoblastic Leukemia; Myeloid-Suppressive Therapeutic Approach Based on Allogeneic Hematopoietic Cell Transplantation May Benefit in Early T-Cell Precursor Acute Lymphoblastic Leukemia

医学 阿糖胞苷 移植 髓样 长春新碱 造血干细胞移植 免疫学 内科学 癌症研究 肿瘤科 髓系白血病 米托蒽醌 化疗 环磷酰胺
作者
Jae‐Ho Yoon,Han Bi Lee,Gi June Min,Sung‐Soo Park,Silvia Park,Byung Sik Cho,Ki‐Seong Eom,Yoo‐Jin Kim,Hee‐Je Kim,Chang‐Ki Min,Seok‐Goo Cho,Jong Wook Lee,Seok Lee
出处
期刊:Blood [Elsevier BV]
卷期号:134 (Supplement_1): 1470-1470
标识
DOI:10.1182/blood-2019-129870
摘要

Background: Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a recently recognized high-risk subgroup of T-cell ALL. T-cell ALL is characterized by poorer survival outcomes compared to B-cell ALL, but the optimal treatment strategies are not well elucidated yet. Aim: We performed integrative genetic analyses and tried to find important genetic events in T-cell ALL. We also identified clinical outcomes of T-cell ALL including ETP-ALL subgroup, which were treated with myeloid-suppressive chemotherapy followed by allogeneic hematopoietic cell transplantation (allo-HCT) for post-remission therapy. Methods: We enrolled 40 adult patients with T-cell ALL for analyses of gene mutations and treatment outcomes. Integrative genetic analyses were performed with massive parallel sequencing for NOTCH1, FBXW7, DNMT3A, PHF6, RUNX1, KRAS, NRAS, PTEN, GATA3, EZH2 and SH2B3, and multiplex ligation-dependent probe amplification (MLPA) for copy number alterations of several genes. Among them, quantification of CDKN2A and CDKN2B mRNA expression was performed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). All were treated with myeloid-suppressive chemotherapy which consisted of hyper-fractionated cyclophosphamide (300 mg/BSA, every 12 h, days 1-3), vincristine (1.4 mg/BSA, maximum dose 2 mg, days 4 and 11), daunorubicin (45 mg/m2, days 4 and 11), and dexamethasone (40 mg, days 1-4 and days 11-14) for remission induction, followed by consolidation with high-dose cytarabine (2 g/BSA, every 12 h, days 1-5) and mitoxantrone (12 mg/BSA, days 1-2). Above two anthracycline-intensified regimens were alternatively used for further consolidation. For patients not in complete remission (CR), mitoxantrone (12 mg/BSA, d 1-4), cytarabine (2 g/BSA, every 12 h, d 1-4) and etoposide (100 mg/BSA, d 5-7) were used for reinduction. Our strategy for T-cell ALL in CR was to offer allo-HCT according to the donor availability. Results: We identified 16 patients with ETP-ALL presenting 1 or more stem cell or myeloid marker with absence of CD1a, CD5, and CD8 expression, and 24 patients with non-ETP-ALL. For genetic mutation profiles between ETP-ALL and non-ETP-ALL, we found DNMT3A was more frequently observed in ETP-ALL (25% vs. 12.5%), while FBXW7 (33.3% vs. 6.2%) and RUNX1 (25.0% vs. 0.0%) were more frequently observed in non-ETP-ALL. We also observed that CDKN2A expression was significantly higher in ETP-ALL (0.053 vs. 0.001, p=0.017). In total, 33 (82.5%) patients achieved CR (24 after induction, 9 after reinduction) and their estimated 5-year overall survival (OS) was 31.3% with median survival of 18.9 months. All 16 (100%) patients with ETP-ALL achieved CR (13 after induction, 3 after reinduction), while non-ETP-ALL in 17 (70.8%, 11 after induction, 6 after reinduction) patients. Estimated 5-year OS of ETP-ALL was 41.7% and non-ETP-ALL was 24.3% (p=0.135). Finally, 12 (75.0%) out of 16 ETP-ALL and 11 (45.8%) out of 24 non-ETP-ALL underwent allo-HCT in CR and their 5-year OS was 55.6% and 45.5%, respectively. Conclusion: Our data suggested different genetic predisposition between ETP-ALL and non-ETP-ALL and myeloid-suppressive chemotherapy showed a good CR rate in ETP-ALL. Myeloid-suppressive chemotherapy induced CR followed by post-remission allo-HCT can be a good solution for improving poor survival outcome of ETP-ALL. Disclosures Kim: Celgene: Consultancy, Honoraria; Astellas: Consultancy, Honoraria; Hanmi: Consultancy, Honoraria; AGP: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; SL VaxiGen: Consultancy, Honoraria; Novartis: Consultancy; Amgen: Honoraria; Chugai: Honoraria; Yuhan: Honoraria; Sanofi-Genzyme: Honoraria, Research Funding; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Handok: Honoraria; Janssen: Honoraria; Daiichi Sankyo: Honoraria, Membership on an entity's Board of Directors or advisory committees; Otsuka: Honoraria; BL & H: Research Funding. Lee:Alexion: Consultancy, Honoraria, Research Funding; Achillion: Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刘芋叶完成签到,获得积分10
刚刚
luis完成签到,获得积分10
1秒前
牛iu完成签到,获得积分10
2秒前
星海种花完成签到 ,获得积分10
2秒前
山不见我发布了新的文献求助10
3秒前
巧依完成签到,获得积分10
4秒前
香香香完成签到,获得积分10
4秒前
龙龙龙发布了新的文献求助30
4秒前
踏实翠丝完成签到,获得积分10
4秒前
4秒前
JamesPei的应助被辛勤的乌采纳,获得10
4秒前
5秒前
5秒前
Fun_112发布了新的文献求助10
5秒前
悲伤肉丸完成签到 ,获得积分10
5秒前
5秒前
姝涵完成签到,获得积分10
5秒前
5秒前
路路完成签到,获得积分10
5秒前
铜板还太少的应助被李思超采纳,获得50
5秒前
6秒前
7秒前
不爱喝酒的应助被iris采纳,获得10
7秒前
华生发布了新的文献求助10
7秒前
大方抽屉完成签到,获得积分20
7秒前
7秒前
奇点发布了新的文献求助30
8秒前
9秒前
ahua15s完成签到,获得积分10
9秒前
kelly完成签到,获得积分10
9秒前
9秒前
猫爪发布了新的文献求助10
11秒前
谁便发布了新的文献求助10
12秒前
12秒前
12秒前
伶俐的高烽完成签到,获得积分10
12秒前
NNKK发布了新的文献求助10
12秒前
大方抽屉发布了新的文献求助10
12秒前
彭于晏的应助被Cindy采纳,获得10
13秒前
Owen的应助被迷人的Jack采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175394
求助须知:如何正确求助?哪些是违规求助? 9567162
关于积分的说明 21790622
捐赠科研通 7769924
什么是DOI,文献DOI怎么找? 3431849
关于科研通互助平台的介绍 2556215
邀请新用户注册赠送积分活动 2477281